Introduction
Loss of function of the ASNS gene has been reported to cause a rare and severe neurologic disorder. Ruzzo et al. reported the first characterization of ASNS deficiency (ASNSD) in four families presenting with congenital microcephaly, intellectual disability, progressive cerebral atrophy, intractable seizures, and recessive mutations in ASNS [1] . To date, ASNS deficiency has been reported in 16 cases evaluated for a range of brain abnormalities coupled with epileptic encephalopathy and global developmental delay. ASNS is expressed in most mammalian cells and encodes an enzyme that catalyzes the transfer of ammonia from glutamine to aspartic acid to form asparagine [2] . We report two novel compound heterozygous variants in ASNS using DNA isolated from archived newborn blood spots collected as part of a routine neonatal screening program.
Case
The proband was a 32-week neonate delivered following preterm labor who presented with clonic tremors, microcephaly, cerebellar hypoplasia, blindness, and seizures. Karyotype, microarray, and metabolic testing were all normal. MRI revealed increased extra-axial space, foreshortened frontal lobe, diffuse simplified gyral pattern more severe frontally, small, normal basal ganglia and thalami, reduced volume of white matter, mildly enlarged third and lateral ventricle, cavum septum pellucidum et vergae, thin corpus callosum, and mild brainstem hypoplasia due to flat base of the pons, and moderate cerebellar hypoplasia. The child had congenital microcephaly with low-sloping forehead, hypertonia, developmental delay, moderate sleep apnea, gastrointestinal reflux, epilepsy, and died at 15 months of age without a definitive diagnosis. Two years after the death of the child the MAF format); SIFT (SIFT prediction and score); PolyPhen (PolyPhen prediction and score). Asterisk (*) before NM_ indicates that the original publication did not specify the transcript identifier and was inferred from the reported variation. 
Methods
We received filter paper with one dried blood spot. Punch biopsies of the spots (3 mm) were placed directly in 20 ll of lysis solution from the Extract-N-Amp kit (Sigma-Aldrich, St. Louis, MO, USA). DNA was isolated following the manufactures protocol. Whole genome amplification was performed in duplicate using the Replig Amplification kit (Qiagen, Hilden, Germany). Peripheral blood drawn from both parents was obtained and DNA isolated using standard methods in the clinical laboratory. An exome library was prepared using SureSelectXT Human All Exon V5+UTR kit (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer's protocol. Paired-end WES was performed on the HiSeq 2500 (Illumina, San Diego, CA, USA) to provide a mean sequence coverage of more than 100x with 98% of the target bases at least 20x coverage.
Data analysis
Data preprocessing was performed following the GATK best practices guidelines as follows Raw reads were aligned to NCBI genome build 37 using Burrows-Wheeler Aligner (BWA) [3] . Picard tools were used to mark duplicate reads [4] . Base Quality Score Recalibration (BQSR) was performed using Genome Analysis Toolkit (GATK) [5] . Local realignment around indels was performed using GATK. Variant discovery was performed in two steps: Single-sample variant calls were discovered using GATK HaplotypeCaller. This was followed by jointly genotyping the single-sample gVCFs for the family along with gVCFs from 50 matched samples. Variant Quality Score Recalibration (VQSR) was performed using GATK. Truth sensitivity thresholds of 99.8 and 99.0 were used for SNVs and INDELs, respectively. Variant effects were predicted using SnpEff [6] .
Additional annotations including variant frequencies in different populations, cross species conservation scores, functional prediction scores, variant disease associations, regulatory annotations, and gene ontology annotations were performed using BCFtools [7] and in-house software. Pedigree-aware variant categorization and functional prioritization were performed using software developed in-house.
Results
A dried blood spot (DBS) typically provides a very limited amount of starting material for DNA extraction and library preparation invariably requiring whole genome amplification (WGA) to achieve sufficient DNA for exome capture. Accordingly, to establish the quality of the DNA library derived from the DBS, we extensively analyzed sequencing quality (Table S1 ) compared with peripheral whole blood specimens. DBS and whole blood exome libraries showed comparable performance across all metrics evaluated. We achieved 264x mean target coverage for the proband while the parents were covered at 144x and 152x. There was a marginal increase in the number of bases covered outside the exome target region (off-target coverage) and AT dropout for the DBS library as compared to whole blood. Both differences are within acceptable ranges and expected to have little or no effect on the variant calling owing to (1) 
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NM_001673.4:c.728T>C is a rare variant, reported at a minor allele frequency of 0.0002 and 0.000008 in 1000 Genomes and ExAC, respectively with no homozygous G/ G genotype reported in either databases. Proband and parental genotypes were confirmed by Sanger sequencing. Considering the in-silico predictions, location in the protein, extreme rarity in the population, and functional studies of variants in the vicinity, both variants are expected to affect the function of asparagine synthetase domain which is crucial for the function of ASNS.
Discussion
Recessive mutations in the ASNS gene have been shown to cause a syndrome characterized by congenital microcephaly, intellectual disability, progressive cerebral atrophy, and intractable seizures. Asparagine synthetase enzyme catalyzes ammonia transfer from glutamine to aspartic acid via a beta-aspartyl-AMP intermediate. [11] [12] [13] [14] . An annotated list of variants including our case and the reported cases in the literature is compiled in Table 1 and Figure 1 . Based on sequence similarity, several active binding sites have been identified for ASNS including amino acid 365 (one amino acid upstream of NP_001664.3:p.Gly366Glu) which is important for beta-aspartyl-AMP intermediate formation. Additionally, amino acids 363-364 have been identified as the protein region which binds nucleotide phosphates. Taken together, and based on available data, the novel NP_001664.3:p.Gly366Glu change we identified appears to be crucial for enzymatic activity.
The NM_001673.4:c.1097G>A variant has not been reported in any public database while one heterozygous NM_001673.4:c.728T>C variant has been reported in 60481 individuals available in ExAC. The extreme rarity of both variants indicates mutational intolerance and functional importance. Considering the known association of ASNS to neurologic phenotypes along with the extreme rarity of both, NM_001673.4:c.1097G>A and NM_00167 3.4:c.728T>C variants and their proximity to known functionally important locations, we conclude that the compound heterozygous missense variants we report are relevant and most likely the cause of the phenotype in this child. Table 2 shows a summary of the common phenotypes described in the reported ASNSD cases. Based on the comparison of the reported phenotypic features of these cases, severe developmental delay, microcephaly, and seizures seem to be the hallmark of ASNSD in majority of reported cases. On the MRI, cerebellar hypoplasia, pontine hypoplasia, and simplified gyral pattern were reported in the majority of cases. Plasma asparagine levels do not seem to be a diagnostic marker for ASNSD.
It is questionable whether earlier knowledge of the causative alterations in asparagine synthesis would have changed the course of the disease in this child. Asparagine is required for normal brain development and is a nonessential amino acid in humans. Synthesized from oxaloacetate precursors using central metabolic pathway intermediates, Asparagine can alternatively be obtained by nutritional intake of various animal or plant products. Alrifai et al. [15] evaluated the effect of asparagine supplementation on mental status and seizures in one of the two individuals reported earlier [11] . After starting asparagine supplementation, the mental status improved slightly from the vegetative state to a minimally conscious state. However, on continuation of the treatment, the patient became irritable, developed sleep disturbance, and experienced worsening seizures leading to discontinuation of the treatment. Additional research and data are required to determine if such intervention could be effective in correcting the deficiency and reducing the detrimental effects of ASNS depletion in the brain. The knowledge of these mutations was valuable for this couple in planning future pregnancies with the availability of either preimplantation genetic diagnosis or prenatal testing.
Conclusions
We report novel compound heterozygous missense variants in asparagine synthetase gene as the likely cause of fatal asparagine synthetase deficiency in a child delivered 
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